ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,024Medicare Part D Prescriptions Filled, Including Refills

Rank: 34 out of 229

$449K Total Retail Price of All Prescriptions

Rank: 56 out of 229

737 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
21% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 737 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

11% of this provider’s 737 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

2% of this provider’s 8,848 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LEVOTHYROXINE SODIUM 983 934 1 1
LISINOPRIL 589 537 2 2
LOSARTAN POTASSIUM 526 510 3 12
METOPROLOL SUCCINATE 441 421 4 16
SIMVASTATIN 409 350 5 3
OMEPRAZOLE 300 235 6 4
LOVASTATIN 286 278 7 11
METFORMIN HCL 261 183 8 6
HYDROCODONE-ACETAMINOPHEN 256 159 S3 9 7
GABAPENTIN 184 152 10 10
METOPROLOL TARTRATE 183 176 11 13
AMLODIPINE BESYLATE 173 164 12 5
ALENDRONATE SODIUM 147 147 13 14
ATENOLOL 146 141 14 19
TRAMADOL HCL 145 139 15 26
ZOLPIDEM TARTRATE 140 115 16 20
ALLOPURINOL 131 123 17 27
TAMSULOSIN HCL 126 125 18 24
CITALOPRAM HBR 112 101 19 21
ATORVASTATIN CALCIUM 111 96 20 15
WARFARIN SODIUM 106 87 21 17
FELODIPINE ER 102 102 22 61
TORSEMIDE 97 93 23 240
DOXAZOSIN MESYLATE 90 88 24 50
RANITIDINE HCL 89 80 25 32
TRAZODONE HCL 88 76 26 34
LOSARTAN-HYDROCHLOROTHIAZIDE 85 81 27 65
FLUTICASONE PROPIONATE 84 82 28 23
FENOFIBRATE 82 66 29 68
SERTRALINE HCL 81 74 30 22
FUROSEMIDE 80 78 31 8
FINASTERIDE 76 75 32 55
METHOCARBAMOL 69 39 R 33 137
GLIPIZIDE 69 69 33 36
PANTOPRAZOLE SODIUM 68 57 35 33
HYDROCHLOROTHIAZIDE 65 62 36 9
TRIAMTERENE-HCTZ 65 61 36 51
CARVEDILOL 63 63 38 31
DONEPEZIL HCL 61 61 39 29
LISINOPRIL-HYDROCHLOROTHIAZIDE 61 48 39 28
OXYCODONE HCL 55 34 S2 41 37
ZETIA 52 52 42 93
TERAZOSIN HCL 51 51 43 74
PROAIR HFA 51 40 43 38
CLOPIDOGREL 51 51 43 44
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 17, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.